These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9354925)

  • 1. Using and interpreting surrogate end-points in cancer research.
    Schatzkin A; Freedman LS; Dorgan J; McShane L; Schiffman MH; Dawsey SM
    IARC Sci Publ; 1997; (142):265-71. PubMed ID: 9354925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end points in cancer research: a critique.
    Schatzkin A; Freedman LS; Dorgan J; McShane LM; Schiffman MH; Dawsey SM
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):947-53. PubMed ID: 8959315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate effect markers for colorectal cancer.
    Baron JA
    IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biological markers as predictive early-outcome measures in epidemiological research.
    McMichael AJ; Hall AJ
    IARC Sci Publ; 1997; (142):281-9. PubMed ID: 9354927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PASSCLAIM--diet-related cancer.
    Rafter J; Govers M; Martel P; Pannemans D; Pool-Zobel B; Rechkemmer G; Rowland I; Tuijtelaars S; van Loo J
    Eur J Nutr; 2004 Jun; 43 Suppl 2():II47-II84. PubMed ID: 15221354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise and peril of surrogate end points in cancer research.
    Schatzkin A; Gail M
    Nat Rev Cancer; 2002 Jan; 2(1):19-27. PubMed ID: 11902582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems with using biomarkers as surrogate end points for cancer: a cautionary tale.
    Schatzkin A
    Recent Results Cancer Res; 2005; 166():89-98. PubMed ID: 15648185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent notions on intestinal cancerogenesis, their implications in genetic risk screening and preventive action of non-steroid anti-inflammatory agents].
    Couturier D
    Bull Acad Natl Med; 2002; 186(2):421-43; discussion 443-5. PubMed ID: 12145848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surgery on the development of duodenal cancer in patients with familial adenomatous polyposis.
    Biasco G; Nobili E; Calabrese C; Sassatelli R; Camellini L; Pantaleo MA; Bertoni G; De Vivo A; Ponz De Leon M; Poggioli G; Bedogni G; Venesio T; Varesco L; Risio M; Di Febo G; Brandi G
    Dis Colon Rectum; 2006 Dec; 49(12):1860-6. PubMed ID: 17103055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of o-Nitroanisole (CAS No. 91-23-6) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 May; 416():1-482. PubMed ID: 12616295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise clinical trials in cancer prevention research: a call to action.
    McTiernan A; Schwartz RS; Potter J; Bowen D
    Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):201-7. PubMed ID: 10090297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in colorectal cancer.
    Owen RW
    IARC Sci Publ; 2001; 154():101-11. PubMed ID: 11220650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
    Mathers JC; Mickleburgh I; Chapman PC; Bishop DT; Burn J;
    Proc Nutr Soc; 2003 Feb; 62(1):51-7. PubMed ID: 12740057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histopathology and tumor markers].
    Kijima H; Ueyama Y; Osamura Y
    Rinsho Byori; 2003 Dec; 51(12):1203-15. PubMed ID: 14743744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.